| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | Inluriyo (imlunestrant) - (EMBER-3) | ER+/HER2– advanced or metastatic breast cancer (MBC) | Phase 3 | Data Released | oral | Oncology |
| Eli Lilly and Company | Jaypirca (pirtobrutinib) - (BRUIN CLL-322) | Chronic Lymphocytic Leukemia | Phase 3 | Ongoing | Oral | Oncology |
| Eli Lilly and Company | Mounjaro (tirzepatide) - (SURPASS-CVOT) | Type 2 diabetes and heart disease | Phase 3 | Data Released | Subcutaneous | Endocrinology |
| Eli Lilly and Company | sofetabart mipitecan (LY4170156) | Platinum-resistant ovarian cancer | Phase 3 | Ongoing | oral | Oncology |
| Eli Lilly and Company | Tirzepatide (LY3298176) - (SURMOUNT-2) | Obesity | Phase 3 | Data Released | Subcutaneous | Endocrinology |
| Eli Lilly and Company | Mirikizumab | Psoriasis | Phase 3 | Subcutaneous | Immunology | |
| Eli Lilly and Company | Tibulizumab (ZB-106) - (TibuSURE) | Systemic Sclerosis | Phase 2 | Enrollment Initiation | Intravenous | Immunology |
| Eli Lilly and Company | JARDIANCE (empagliflozin) | Heart failure with preserved ejection fraction (HFpEF) | Phase 3 | Oral | Cardiology |